Forbes December 5, 2023
Ellen Matloff

Victoria Gray never remembers a moment when she didn’t have sickle cell disease. She was diagnosed with the condition at 3 months of age after she cried so hard during a bath that she was taken to the emergency room. For Gray, who has no close relatives with the disorder, that was the beginning of unrelenting pain, ER visits, hospitalizations and treatments that robbed her of much of her childhood and adult life.

Gray became unable to take care of herself and her family. In hopes that she could improve her life by even 50%, Gray bravely chose to be the first patient to enter a clinical trial using a CRISPR editing drug to treat sickle cell disease. Four and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article